What do systematic reviews say?

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 1.4 [0.44, 4.42]
  1 study · 56 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 2.8 [1.14, 6.89]
  1 study · 33 participants
  Moderate

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Low

Osmotic‐release oral system methylphenidate vs placebo

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 33 participants
  Moderate

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 56 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  RR 0.65 [0.12, 3.59]
  1 study · 61 participants
  Low

Omega‐3 (with risperidone and previous ASM) vs risperidone and previous ASM only

The review found no eligible studies for this question.

• Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor showed no clear difference in overall adverse events compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 1 [0.98, 1.01]
  5 studies · 1263 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor showed no clear difference in grade 5 adverse events (excluding progressive disease) compared with crizotinib (low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 0.85 [0.49, 1.47]
  5 studies · 1263 participants
  Low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor probably leads to lower overall survival compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.71 [0.56, 0.9]
  5 studies · 1263 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor probably leads to higher overall response rate compared with crizotinib (moderate certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  RR 1.18 [1.1, 1.25]
  5 studies · 1229 participants
  Moderate

Next‐generation ALK inhibitor vs crizotinib

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 1.1 [0.72, 1.68]
  1 study · 303 participants
  Very low

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival: overall population compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.39 [0.32, 0.46]
  5 studies · 1263 participants
  High

Next‐generation ALK inhibitor vs crizotinib

Next‐generation ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with crizotinib (high certainty).

• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
  HR 0.25 [0.19, 0.34]
  5 studies · 406 participants
  High

NPWT vs the Bogota bag

It is very uncertain whether NPWT changes time to primary fascial closure of the abdomen compared with the Bogota bag (very low certainty).

• Negative pressure wound therapy for managing the open abdomen in non‐trauma patients 2022 · Cochrane Headline outcomes only
  MD 3.6
  1 study · 40 participants
  Very low

Suprasorb CNP system vs the ABThera system

The review found no eligible studies for this question.

• Negative pressure wound therapy for managing the open abdomen in non‐trauma patients 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

NPWT vs the Bogota bag

The review found no eligible studies for this question.

• Negative pressure wound therapy for managing the open abdomen in non‐trauma patients 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found